A new treatment option is now available from Pfizer Canada for Canadians who suffer from migraine. Relpax™ (eletriptan hydrobromide) has been shown in clinical studies that it can provide relief in as early as 30 minutes following use. Relpax tablets are available by prescription and are indicated for the acute treatment of migraine with or without aura in adults.

The efficacy of Relpax has been demonstrated and supported in numerous clinical trials. In all studies, the percentage of patients achieving headache response two hours after treatment was significantly greater among patients receiving Relpax tablets compared to those who received a placebo. Headache response occurred in as little as 30 minutes following dosing.

The proportion of patients achieving pain-free status (decrease in pain from moderate to severe, to absence of pain) at two hours was also statistically significant. A decreased incidence of sensitivity to light and sound, and nausea in patients experiencing migraines with those symptoms was observed in patients receiving Relpax. Sixty-eight per cent of patients treated with Relpax returned to normal, or near normal, levels of functioning within two hours post-dose.

The safety and tolerability of Relpax has been demonstrated and supported by the treatment of more than 11,000 subjects and 74,000 migraine attacks in clinical trial.

About Relpax
Relpax is a product in the class of drugs known as “triptans.” The maximum daily dose of Relpax is 40 mg. Relpax tablets should be taken as early as possible after the onset of a migraine attack, but are also effective if taken at a later stage. Relpax tablets should be swallowed whole with water and should only be used where a clear diagnosis of migraine has been established. The most common side effects reported with treatment with Relpax were asthenia (weakness), nausea, dizziness and somnolence. Events seen with Relpax are similar to those reported with triptans as a class. Complete Relpax safety information is available in the Product Monograph.

Relpax has received regulatory approval in 73 countries including the U.S. and European Union member countries, among others.

SOURCE: Pfizer Canada Inc.